Yamazaki, Takahiro http://orcid.org/0000-0002-7420-4394
Kirchmair, Alexander http://orcid.org/0000-0003-2284-7424
Sato, Ai http://orcid.org/0000-0002-5408-2596
Buqué, Aitziber http://orcid.org/0000-0002-7698-8778
Rybstein, Marissa
Petroni, Giulia http://orcid.org/0000-0002-0558-5322
Bloy, Norma http://orcid.org/0000-0001-5758-9424
Finotello, Francesca http://orcid.org/0000-0003-0712-4658
Stafford, Lena http://orcid.org/0000-0002-7145-8022
Navarro Manzano, Esther http://orcid.org/0000-0002-0243-0085
Ayala de la Peña, Francisco http://orcid.org/0000-0001-6311-920X
García-Martínez, Elena http://orcid.org/0000-0003-4775-5681
Formenti, Silvia C. http://orcid.org/0000-0002-8227-8924
Trajanoski, Zlatko http://orcid.org/0000-0002-0636-7351
Galluzzi, Lorenzo http://orcid.org/0000-0003-2257-8500
Article History
Received: 7 December 2019
Accepted: 23 June 2020
First Online: 3 August 2020
Competing interests
: F.A.P. declares research funding from Celgene and Roche and speaker and/or advisory honoraria from Pfizer, Roche, AstraZeneca, Celgene, Eisai, Novartis, Pierre Fabre and Roche. E.G.M. declares research funding from Roche and speaker and/or advisory honoraria from AstraZeneca, Roche and Pharmamar. S.C.F. declares funding for clinical trials from Bristol Myers Squibb, Merck and Varian and speaker and/or advisory honoraria from Astra Zeneca, Bayer, Bristol Myers Squibb, Eisai, Elekta, EMD Serono/Merck, GlaxoSmithKline, Janssen, MedImmune, Merck US, Regeneron, Varian and ViewRay. L.G. declares research funding from Lytix Biopharma and Phosplatin Therapeutics and speaker and/or advisory honoraria from Boehringer Ingelheim, Astra Zeneca, OmniSEQ, the Longevity Labs, Inzen and the Luke Heller TECPR2 Foundation.